Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000029602
JPRN-UMIN000029602
Completed
未知

Safety and efficacy of pembrolizumab as first-line treatment in elderly patients with non-small cell lung cancer: a pilot study. - A pilot study of pembrolizumab as first-line treatment in elderly patients with non-small cell lung cancer

Department of Respiratory Internal medicine, Hiroshima Univestity Hospital0 sites35 target enrollmentOctober 18, 2017
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionson-small cell lung cancer

Overview

Phase
未知
Intervention
Not specified
Conditions
on-small cell lung cancer
Sponsor
Department of Respiratory Internal medicine, Hiroshima Univestity Hospital
Enrollment
35
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 18, 2017
End Date
March 5, 2020
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Department of Respiratory Internal medicine, Hiroshima Univestity Hospital

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •1\) Pleural effusion, ascites or pericardialeffusion requiring drainage 2\) Other cancers 3\) Symptomatic brain metastasis and meningitis 4\) With severe complication 5\) Interstitial pneumonia on CT 6\) Severe drug allergy 7\) Active autoimmune disease that has required systemic treatment 8\) Dementia 9\) Other conditions not suitable for this study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Safety and efficacy of pembrolizumab as first-line treatment in non-small cell lung cancer patients with poor performance status: a pilot study.non-small cell lung cancer
JPRN-UMIN000029601Hiroshima University Hospital30
Recruiting
Phase 2
Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPDNSCLC With COPD
NCT05578222Tianjin Chest Hospital30
Recruiting
Phase 2
pembrolizumab plus axitinib trialrenal cell carcinoma
JPRN-jRCT1061200062Takehiro Iawata7
Active, not recruiting
Phase 1
A Phase II Study of Pembrolizumab in Subjects with Gastric CancerGastric CancerTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2014-003574-16-FRMerck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.270
Active, not recruiting
Phase 1
A Phase II Study of Pembrolizumab in Subjects with Gastric CancerGastric CancerTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2014-003574-16-LTMerck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.253